A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic

- Lal, Anoushka P., Foong, Yi Chao, Roos, Izanne, Lechner-Scott, Jeannette, John, Nevin, Soysal, Aysun, D’Amico, Emanuele, Gouider, Riadh, Mrabet, Saloua, Gross-Paju, Katrin, Cárdenas‑Robledo, Simón, Moghadasi, Abdorreza Naser, Sanfilippo, Paul G., Sa, Maria Jose, Gray, Orla, Oh, Jiwon, Reddel, Stephen, Ramanathan, Sudarshini, Al-Harbi, Talal, Altintas, Ayse, Hardy, Todd A., Ozakbas, Serkan, Alroughani, Raed, Spelman, Tim, Kermode, Allan G., Surcinelli, Andrea, Laureys, Guy, Eichau, Sara, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Hodgkinson, Suzanne, Ramo-Tello, Cristina, Maimone, Davide, Rath, Louise, McCombe, Pamela, Spitaleri, Daniele, Sanchez-Menoyo, Jose Luis, Yetkin, Mehmet Fatih, Baghbanian, Seyed Mohammad, Karabudak, Rana, Al-Asmi, Abdullah, Jakob, Gregor Brecl, Khoury, Samia J., Etemadifar, Masoud, Levitz, David, van Pesch, Vincent, Buzzard, Katherine, Taylor, Bruce, Butzkueven, Helmut, Van der Walt, Anneke, Fabis-Pedrini, Marzena, Foschi, Matteo, Habek, Mario, Kalincik, Tomas

Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation

- Zhu, Chao, Kalincik, Tomas, Patti, Francesco, Grand'Maison, Francois, Hodgkinson, Suzanne, Grammond, Pierre, Lechner-Scott, Jeannette, Butler, Ernest, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Macdonell, Richard A. L., Horakova, Dana, Weinstock-Guttman, B, Ozakbas, S, Slee, M, Sa, MJ, Van Pesch, V, Barnett, M, Van Wijmeersch, B, Gerlach, O, Prevost, J, Terzi, M, Zhou, Zhen, Boz, C, Laureys, G, Van Hijfte, L, Kermode, AG, Garber, J, Yamout, B, Khoury, SJ, Merlo, D, Monif, M, Jokubaitis, V, Buzzard, Katherine, van der Walt, A, Butzkueven, H, MSBase, SG, Skibina, Olga, Alroughani, Raed, Izquierdo, Guillermo, Eichau, Sara, Kuhle, Jens

Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis

- Zhu, Chao, Zhou, Zhen, Roos, Izanne, Merlo, Daniel, Kalincik, Tomas, Ozakbas, Serkan, Skibina, Olga, Kuhle, Jens, Hodgkinson, Suzanne, Boz, Cavit, Alroughani, Raed, Lechner-Scott, Jeannette, Barnett, Michael, Izquierdo, Guillermo, Prat, Alexandre, Horakova, Dana, Havrdova, Eva Kubala, Macdonell, Richard, Patti, Francesco, Khoury, Samia Joseph

Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts

- Sharmin, Sifat, Lefort, Mathilde, Onofrj, Marco, Lugaresi, Alessandra, Terzi, Murat, Grammond, Pierre, Grand'Maison, Francois, Yamout, Bassem, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Boz, Cavit, Andersen, Johanna Balslev, Trojano, Maria, McCombe, P, Slee, M, Lechner-Scott, Jeannette, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Prevost, J, Maimone, D, Leray, Emmanuelle, Skibina, O, Buzzard, K, Van der Walt, A, Van Wijmeersch, B, Csepany, T, Spitaleri, D, Vucic, S, Casey, R, Debouverie, M, Edan, G, Horakova, Dana, Ciron, J, Ruet, A, De Seze, J, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun-Frenay, C, Moreau, T, Berger, E, Havrdova, Eva Kubala, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Alroughani, Raed, Montcuquet, A, Wahab, A, Camdessanche, J-P, Maurousset, A, Patry, I, Hankiewicz, K, Pottier, C, Maubeuge, N, Labeyrie, C, Nifle, C, Izquierdo, Guillermo, Laplaud, D, Koch-Henriksen, N, Sellebjerg, FT, Soerensen, PS, Pfleger, CC, Rasmussen, PV, Jensen, MB, Frederiksen, JL, Bramow, S, Mathiesen, HK, Ozakbas, Serkan, Schreiber, KI, Magyari, M, Vukusic, S, Butzkueven, H, Kalincik, T, Patti, Francesco

The effectiveness of natalizumab vs fingolimod - A comparison of international registry studies

- Andersen, Johanna B., Sharmin, Sifat, Lefort, Mathilde, Koch-Henriksen, Nils, Sellebjerg, Finn, Sørensen, Per Soelberg, Hilt Christensen, Claudia C., Rasmussen, Peter V., Jensen, Michael B., Frederiksen, Jette L., Bramow, Stephan, Mathiesen, Henrik K., Schreiber, Karen I., Horakova, Dana, Havrdova, Eva K., Alroughani, Read, Izquierdo, Guillermo, Eichau, Sara, Ozakbas, Serkan, Patti, Francesco, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, Jenette, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Shaygannejad, V, Prevost, J, Skibina, O, Solaro, C, Karabudak, R, Wijmeersch, BV, Csepany, T, Spitaleri, D, Vucic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, Sèze, JD, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanché, JP, Marousset, A, Patry, I, Hankiewicz, K, Pottier, C, Maubeuge, N, Labeyrie, C, Nifle, C, Leray, E, Laplaud, DA, Butzkueven, H, Kalincik, T, Vukusic, S, Magyari, M

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis

- Kalincik, Tomas, Jokubaitis, Vilja, Duquette, Pierre, Grammond, Pierre, Solaro, Claudio, Grand'Maison, Francois, Hupperts, Raymond, Prevost, Julie, Sola, Patrizia, Ferraro, Diana, Terzi, Murat, Butler, Ernest, Spelman, Tim, Slee, Mark, Kermode, Allan, Fabis-Pedrini, Marzena, McCombe, Pamela, Barnett, Michael, Shaw, Cameron, Hodgkinson, Suzanne, Butzkueven, Helmut, MSBase Study Group,, Horakova, Dana, Havrdova, Eva, Trojano, Maria, Lechner-Scott, Jeannette, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

- Kalincik, Tomas, Brown, J. William L., McGuigan, Christopher, Jokubaitis, Vilija, Spelman, Tim, Horakova, Dana, Havrdova, Eva, Trojano, Maria, Izquierdo, Guillermo, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Robertson, Neil, Lechner-Scott, Jeannette, Willis, Mark, Scolding, Neil, Rice, Claire M., Wilkins, Alastair, Pearson, Owen, Ziemssen, Tjalf, Hutchinson, Michael

Comparative efficacy of switching to natalizumab in active multiple sclerosis

- Spelman, Timothy, Kalincik, Tomas, Grand-Maison, Francois, Izquierdo, Guillermo, Grammond, Pierre, Duquette, Pierre, Lugaresi, Alessandra, Lechner-Scott, Jeannette, Oreja-Guevara, Celia, Hupperts, Raymond, Petersen, Thor, Barnett, Michael, Zhang, Annie, Trojano, Maria, Butzkueven, Helmut, Pellegrini, Fabio, Wiendl, Heinz, Kappos, Ludwig, Tsvetkova, Larisa, Belachew, Shibeshih, Hyde, Robert, Verheul, Freek

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis

- Kalincik, Tomas, Horakova, Dana, Spelman, Tim, Jokubaitis, Vilija, Trojano, Maria, Lugaresi, Alessandra, Izquierdo, Guillermo, Rozsa, Csilla, Grammond, Pierre, Alroughani, Raed, Duquette, Pierre, Girard, Marc, Pucci, Eugenio, Lechner-Scott, Jeannette, Slee, Mark, Fernandez-Bolanos, Ricardo, Grand'Maison, Francois, Hupperts, Raymond, Verheul, Freek, Hodgkinson, Suzanne

Fingolimod after natalizumab and the risk of short-term relapse

- Jokubaitis, Vilija G., Li, Vivien, Barnett, Michael, Grand'Maison, Francois, Trojano, Maria, Slee, Mark, Giuliani, Giorgio, Shaw, Cameron, Boz, Cavit, Spitaleri, Daniele L. A., Verheul, Freek, Haartsen, Jodi, Kalincik, Tomas, Liew, Danny, Butzkueven, Helmut, Izquierdo, Guillermo, Hodgkinson, Suzanne, Alroughani, Raed, Lechner-Scott, Jeannette, Lugaresi, Alessandra, Duquette, Pierre, Girard, Marc